Entyvio patent?

Entyvio (vedolizumab) – a quick snapshot of the patent landscape

How the dates work

• Patent life = 20 years from the earliest priority date (not the publication date).
• Many of Entyvio’s patents were filed between 2004‑2006, so the core sequence patents expire around 2025‑2026.
• Use‑and‑formulation patents, filed later, expire a few years later, around 2031‑2032.

Why the dates matter

• Exclusivity: Until the patents expire, Novartis/Janssen has the legal right to be the sole manufacturer and marketer of Entyvio in the U.S. (and in many other territories).
• Biosimilars: Once a patent expires, other companies can apply for regulatory approval of a biosimilar, provided they meet all FDA or EMA biosimilarity requirements.
• Legal battles: Even after expiration, disputes may arise over “method of use” claims, orphan‑drug status, or secondary patents.

What you should do if you need precise, up‑to‑date information

1. Search USPTO (or the relevant national patent office) for the exact filing dates and current status of each claim.
2. Check the FDA’s “Patent and Exclusivity” database for the drug’s approval history.
3. Review the European Medicines Agency (EMA) documents if you’re interested in the EU market.
4. Consult a qualified IP attorney if you’re planning to launch a biosimilar or if you’re involved in a licensing or litigation matter.

Bottom line

Entyvio is protected by a portfolio of patents that cover the antibody itself, its therapeutic uses, formulation, and manufacturing process. These patents were filed in the mid‑2000s and will expire in the mid‑2020s to early 2030s, after which the market may open up to biosimilar competitors. For any commercial or legal decision, always verify the current legal status through official patent databases or professional counsel.